Background. Despite great progress in the prevention and control of cardiovascular disease, it remains the leading cause of global mortality and morbidity, with new unexpected risk factors emerging and few effective new pharmaceutical treatments. ADAMTS-13 is involved in a clotting disorder, thrombotic thrombocytopenic purpura, for which new treatments are being developed. Observationally, ADAMTS-13 activity is inversely associated with ischemic heart disease (IHD) but positively associated with diabetes. Objectives: To obtain unconfounded estimates of the effect of ADAMTS-13 on IHD, diabetes and lipids. Methods: We applied genetic variants strongly, (P < 5 9 10 À8 ), solely and independently associated with ADAMTS-13 to the largest available extensively genotyped case-control studies of IHD and diabetes and to a large study of lipids to obtain Mendelian randomization inverse variance weighted (IVW) estimates. Sensitivity was evaluated through weighted median and MR-Egger estimates. Results: Genetically predicted ADAMTS-13 activity, based on three genetic variants, was consistently inversely associated with IHD (IVW odds ratio [OR] 0.91 per effect size; 95% confidence interval [CI] 0.86-0.97) but not with diabetes (OR 0.94, 95% CI 0.88-1.01) or high or low-density lipoprotein cholesterol (0.01, 95% CI À0.02 to 0.04; À0.01, 95% CI À0.04 to 0.02, respectively). ADAMTS-13 antigen, based on four genetic variants, was not associated with any outcome. Conclusions: This genetic validation of ADAMTS-13 activity as a target of intervention in IHD raises the possibility of new ways of prevention and treatment being developed by repurposing therapeutics that raise ADAMTS-13 activity, or by other environmental or dietary interventions that raise ADAMTS-13 activity.
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Cardiovascular disease is a leading cause of global morbidity and mortality. Despite great progress in prevention and control, cardiovascular disease remains incompletely understood. For example, rates of myocardial infarction (MI) are higher in men than women at the same level of risk factors [1] . Development of effective new treatments that reduce cardiovascular mortality has proved challenging [2] and many of the current ischemic heart disease (IHD) drugs are not acting on genetically validated targets [3] .
New unexpected risk factors are emerging for cardiovascular disease, such as clonal hematopoiesis [4] , reticulocytes [5] and non-O blood group [6] . These anomalies may be informative. Specifically, O blood group could be protective because it is associated with lower von Willebrand factor. However, it is unclear whether von Willebrand factor causes IHD [7] , potentially implicating related factors. ADAMTS-13 (a disintegrin and metalloprotease with thrombospondin type motif, member 13) interacts with von Willebrand factor. Observationally, ADAMTS-13 activity and antigen are inversely associated with IHD [8, 9] , and ADAMTS-13 activity is positively associated with diabetes [10] . However, observational studies cannot distinguish between biomarkers and causal factors, are open to residual confounding and cannot easily distinguish between correlated factors, such as ADAMTS-13 activity and antigen. Therapies targeting ADAMTS-13 activity are emerging for use in specific conditions, such as thrombotic thrombocytopenic purpura [11] .
In this situation, obtaining genetic validation of ADAMTS-13 as a target of intervention may inform drug repurposing. Previous genetic studies of ADAMTS-13 have been too small to be definitive [12] . Here, we used Mendelian randomization to assess the effects of ADAMTS-13 activity and antigen on IHD, MI and diabetes. We also considered effects via lipids by assessing whether ADAMTS-13 affected low-density lipoprotein (LDL) cholesterol or high-density lipoprotein (HDL) cholesterol.
Methods

Sources of data
We obtained genetic predictors of ADAMTS-13 activity (effect size of % activity) from a genome-wide association study (GWAS) of ADAMTS-13 activity [13] and we obtained genetic predictors of ADAMTS-13 antigen (effect size of % antigen) from a GWAS of ADAMTS-13 antigen [14] . We applied these genetic predictors to the largest publicly available extensively genotyped IHD case (n < 76 014)-control (n < 264 785) study (largely based on the UK Biobank SOFT CAD, CARDIoGRAMplusC4D 1000 Genomes and the MIGen/CARDIoGRAM Exome chip study) [15] . Case status in the UK Biobank was defined as MI, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, chronic IHD and angina based on self-report, hospital episodes or death records [15] . Case status in CARDIoGRAMplusC4D 1000 Genomes was defined as a diagnosis of MI, acute coronary syndrome, angina or coronary stenosis > 50%, ascertained from medical records, clinical diagnosis at the time of the study, procedures, medications, symptoms indicating angina, or self-report of diagnosis by a doctor, as described elsewhere [15] . Double-genomic-control was used [15] . We also applied these genetic predictors to the CARDIoGRAMplusC4D 1000 Genomes MI case (n =~42 561)-control (n = 123 504) study [16] , the DIAGRAM diabetes case (n = 26 676)-control (n = 132 532) study [17] and the Global Lipids Genetics Consortium (GLGC) Results (n = 188 577) [18] . All these studies mainly pertain to people of European descent and use genomic control [16] [17] [18] . DIAGRAM, mean age 57.4 years, adjusted for age, sex, study specific covariates and principal components for ancestry [17] . GLGC gives genetic associations with lipids (inverse normal transformed effect sizes) adjusted for age, sex and where possible principal components for ancestry [18] .
Statistical analysis
Mendelian randomization, as instrumental variable analysis with genetic instruments, has stringent assumptions. First, strong genetic predictors of exposure are required with F-statistic > 10. We only used single nucleotide polymorphisms (SNPs) strongly (P < 5 9 10 À8 ), solely and independently (r 2 < 0.02) associated with ADAMTS-13 activity or antigen. We obtained F-statistics using an approximation [19] . Second, the relation of the genetic predictors of exposure with the outcomes should not be confounded; this is likely to be achieved by taking advantage of random genetic allocation at conception. Third, the SNPs predicting the exposure should only affect the outcomes via the exposure (i.e. be free of pleiotropic effects). We checked the selected SNPs for pleiotropic effects using two comprehensive curated cross-references, Ensembl (http://www.ensembl.org/index.html) and PhenoScanner (http://www.phenoscanner.medschl.cam.ac. uk/phenoscanner), which provide well-established known phenotypes for given SNPs. Finally, we ensured SNPs were aligned in the same way for exposure and outcome by matching palindromic SNPs on effect allele frequency and effect allele. Where an SNP was unavailable for an outcome or could not be unequivocally aligned we replaced it with a correlated (r 2 > 0.5) proxy obtained from LDLink (https://analysistools.nci.nih.gov/LDlink/).
We obtained unconfounded estimates in three complementary ways with different assumptions to check for consistency. We combined SNP-specific Wald estimates (ratio of SNP on outcome to SNP on exposure) using inverse variance weighted (IVW) estimates with fixed effects for three SNPs (i.e. assuming all the SNPs are valid instrumental variables) and multiplicative random effects for more than three SNPs (i.e. assuming balanced pleiotropy) [20] . We used a weighted median, which is valid as long as > 50% of the weight is contributed by valid SNPs because the estimate is essentially the weighted median of the SNPspecific estimates. We used the Mendelian randomization (MR)-Egger method, which is valid as long as the size of the pleiotropic effects is independent of their strength as instruments [19] . A non-zero MR-Egger intercept indicates the IVW estimate may be invalid [19] .
All statistical analyses were conducted using R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria), with the 'Mendelian Randomization' package. Two-sided P-values are reported throughout, with correction for multiple testing using a P-value of 0.05/ 6 = 0.008, given two exposures (ADAMTS-13 activity and antigen) and three classes of outcomes (IHD/MI, diabetes and lipids). This approach balances rigorous results, avoiding false negatives, particularly given the generally low power of Mendelian randomization studies, and the lack of prior justification for favoring the null hypothesis. No institutional review board approval was required because the data are publicly available.
Results
We obtained genetic predictors of ADAMTS-13 activity from a GWAS conducted in 5448 people of European ancestry, mean age of 68 years, 43% men, adjusted for age and sex, with genomic control [13] . Four uncorrelated SNPs (rs41314453 [ADAMTS-13], rs10456544 [SUPT3H], rs3118667 [ADAMTS-13] and rs139911703 [OBP2B]) predicted ADAMTS-13 activity and explained~7% of the variance in ADAMTS-13 activity. As such, at 80% power and 5% alpha for an effect size of ADAMTS-13 activity an odds ratio (OR) of 0.96 for IHD, 0.94 for MI and 0.93 for diabetes can be detected and a 0.024 effect size for lipids [21] . Each SNP had an estimated F-statistic > 30. rs41314453 (p.A732V) is also functionally relevant to ADAMTS-13 activity [22] . rs139911703 was only available for diabetes and did not have any close proxies. Rs10456544 was palindromic with no effect allele frequency for diabetes or lipids, so was replaced by rs10456550 (SUPT3H) for diabetes (r 2 = 0.73) and rs1219021 (r 2 = 0.53) for lipids. Rs41314453 was also unavailable for lipids and replaced by rs3739893 (r 2 = 0.87). The ADAMTS-13 activity SNP rs41314453 was strongly related to the ADAMTS-13 antigen SNP rs3739893 (r 2 = 0.87) and rs3118667 weakly to rs28673647 (r 2 = 0.36). In addition, rs41314453 was weakly correlated with rs3124762 (r 2 = 0.10). We obtained genetic predictors of ADAMTS-13 antigen from a GWAS conducted in 3456 people of European ancestry, mean age of 21.4 years, adjusted for smoking or sex, smoking and body mass index and principal components [14] . Four uncorrelated SNPs (rs28673647 Table 1 Associations of ADAMTS-13 activity [13] and antigen [14] with IHD [15] , MI [16] , diabetes [17] and lipids [18] [14] . As such, at 80% power and 5% alpha for an effect size of ADAMTS-13 antigen an OR of 0.97 for IHD and MI and of 0.96 for diabetes can be detected and a 0.02 effect size for lipids [21] . Rs28673647 was unavailable for lipids and was replaced by rs2301614 (r 2 = 0.77). Each SNP had an estimated F-statistic > 30. None of the genetic predictors of ADAMTS-13 activity or antigen were documented as strongly associated with IHD or MI via other, potentially pleiotropic, pathways. However, rs3118667 is related to the leptin receptor. Genetically instrumented ADAMTS-13 activity was generally inversely associated with IHD (Table 1) . Notably, the SNP functionally relevant to ADAMTS-13 activity, rs41314453, was inversely related to IHD (Fig. 1) . ADAMTS-13 activity had some nominal inverse associations with MI. ADAMTS-13 activity was unrelated to diabetes and lipids. The forest plots for the IVW estimates only displayed heterogeneity for LDL cholesterol (Fig. 1) . The MR-Egger intercepts did not differ from zero, suggesting some validity of the IVW estimates. These findings for IHD are consistent with observational studies [8, 23] . Higher genetically instrumented ADAMTS-13 antigen was not clearly associated with IHD, MI, diabetes or lipids using any method (Table 1 and Fig. 2) . The MR-Egger intercepts did not differ from zero.
This well-powered Mendelian randomization study assessed the role of genetically predicted ADAMTS-13 activity and antigen in IHD, MI, diabetes and lipids using methods providing potentially unconfounded estimates. Fig. 1 . Single nucleotide polymorphism-specific and inverse variance weighted (IVW) estimates for the association of ADAMTS-13 activity [13] with ischemic heart disease [15] , myocardial infarction [16] , diabetes [17] and lipids [18] using Mendelian randomization. Fig. 2 . Single nucleotide polymorphism-specific and inverse variance weighted (IVW) estimates for the association of ADAMTS-13 antigen [14] with ischemic heart disease [15] , myocardial infarction [16] , diabetes [17] and lipids [18] using Mendelian randomization.
Nevertheless, several limitations exist. First, the number of genetic predictors of ADAMTS-13 was limited. However, they explained~7% of the variance of ADAMTS-13 activity [13] and~20% of the variance in ADAMTS-13 antigen [14] . Second, confounding by population stratification or a shared data structure is possible. The genetic associations are all from studies conducted largely in people of European descent with genomic control [13] [14] [15] [16] [17] [18] . The sample used to obtain genetic predictors of ADAMTS-13 activity (n = 5448) is included in studies with the outcomes, but only constitutes a small proportion of these studies, [13] [14] [15] [16] [17] [18] which is unlikely to induce bias.
Third, the genetic predictors of ADAMTS-13 activity were also associated with ADAMTS-13 antigen. We do not have sufficient information to conduct multivariable MR, so we cannot completely disentangle ADAMTS-13 activity from antigen. However, ADAMTS-13 antigen was not associated with IHD or MI. A positive association of ADAMTS-13 antigen with ADAMTS-13 activity could have obscured a positive association of ADAMTS-13 antigen with IHD and MI, making the associations of ADAMTS-13 activity with IHD and MI conservative. The genetic predictors of ADAMTS-13 might also have pleiotropic effects on the outcomes other than via ADAMTS-13. We checked for known potential pleiotropy using several comprehensive genetic cross-reference systems and only found a potential association of rs3118667 with the leptin receptor. The inverse association of ADAMTS-13 activity with IHD was stronger when rs3118667 was excluded (OR 0.88, 95% confidence interval 0.82-0.96). Von Willebrand factor is linked to ABO blood group, but we did not use genetic instruments from the ABO gene, although rs139911703 is in perfect linkage equilibrium with rs36218903 (ABO) [13] . However, we only used rs139911703 for diabetes, where it contributed little. We checked for robustness to unknown pleiotropy by using sensitivity analysis that gave similar estimates.
Fourth, our study was limited mainly to people of European ancestry. However, causal factors should act consistently, but might not be relevant in all settings. Fifth, we did not consider stroke because IHD on average occurs at a younger age than stroke, so factors that cause death from IHD and stroke may appear less harmful or even protective for stroke [24] . Sixth, we could not assess whether associations varied by baseline levels of ADAMTS-13. Seventh, canalization might affect genetic associations. However, the extent to which canalization occurs is unknown. Finally, effects of ADAMTS-13 might differ by sex, which cannot be assessed from the data that are freely available.
ADAMTS-13 activity is lower in men than in women [25] , consistent with the higher risk of MI observed in men after taking established risk factors into account [1] . Physiologically, ADAMTS-13 activity may be inactivated by thrombin and plasmin [26] , consistent with endogenous thrombin potential raising the risk of IHD [7] . Given that ADAMTS-13 was discovered less than 20 years ago [27] , environmental or dietary modulators of ADAMTS-13 activity have not been extensively investigated. In vitro studies suggest statins may raise ADAMTS-13 expression [28] , whereas calcium and sodium chloride may reduce it [29, 30] .
Conclusion
Genetically predicted ADAMTS-13 activity was inversely associated with IHD, which given lower ADAMTS-13 in men than women might be a pathway by which men's greater vulnerability to IHD is potentiated. Given the genetic validation of ADAMTS-13 activity as a cause of IHD, repurposing of existing therapies, identification of the factor driving higher ADAMTS-13 activity in men and greater investigation of the role of modifiable precursors of ADAMTS-13 activity might be worthy of consideration. Whether ADAMTS-13 has a role in any other cardiovascular-related condition might also be considered. 
